Patients with osteoporosis who took bisphosphonates, especially risedronate, were at a higher risk of developing acute angle ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

"Among dialysis patients with osteoporosis, denosumab may be more effective than oral bisphosphonates in reducing fracture ...

In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates.

I am an 81-year-old man (5-foot-2 at 122 pounds) in good health, except that I have Type 2 diabetes. My A1C level has been in ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Researchers have found in a observational study that dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for ...

A controlled study has confirmed moderate but significant efficacy of intravenous bisphosphonate (pamidronate) treatment in patients with AS; further evaluation of bisphosphonate treatment is ...

Study finds dialysis patients taking denosumab have 36% higher risk for major cardiovascular events compared to those taking oral bisphosphonates.